|1.||Joshi, Kalpana S: 7 articles (01/2013 - 03/2007)|
|2.||Rathos, Maggie J: 6 articles (01/2013 - 03/2007)|
|3.||Manohar, Sonal M: 4 articles (01/2013 - 06/2011)|
|4.||Khanwalkar, Harshal: 2 articles (01/2013 - 01/2012)|
|5.||Joshi, Kavita: 2 articles (01/2013 - 01/2012)|
|6.||Sivakumar, Meenakshi: 2 articles (03/2007 - 03/2007)|
|7.||Sharma, Somesh: 2 articles (03/2007 - 03/2007)|
|8.||Nachankar, Rajesh: 1 article (07/2015)|
|9.||Gandhi, Mansi: 1 article (07/2015)|
|10.||Chawla, Purvi: 1 article (07/2015)|
03/01/2007 - "In contrast, the normal cells (WI-38) remain arrested in G(1) with no significant apoptosis up to 72 h of exposure and also after 48 h of P276-00 treatment followed by recovery, confirming our previous results that P276-00 was less effective against normal cells compared with cancer cells. "
07/01/2015 - "In phase I studies of P276-00 in patients with refractory solid neoplasms, it was well-tolerated with a mild trend toward single-agent efficacy. "
01/01/2013 - "We have investigated the anti-cancer activity of P276-00 in head and neck tumors in vitro and in vivo. "
01/01/2013 - "P276-00, a novel CDK inhibitor currently being tested in clinic, inhibits growth of several cancers in vitro and in vivo. "
03/01/2007 - "Further, we studied the effects of P276-00 on cell cycle progression by flow cytometry using asynchronous and synchronous population of tumor and normal cells. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/01/2007 - "To delineate its mechanism of action, the effect of P276-00 on cell cycle proteins was studied in human breast cancer cell line (MCF-7) and human non-small cell lung carcinoma (H-460). "
11/01/2013 - "Valproic acid (VPA), an antiepileptic agent has been associated with anticancer activity, through the inhibition of histone deacetylase I. Here we investigate the effect of the combination of VPA and P276-00, in non-small-cell lung cancer (NSCLC) cell lines. "
01/01/2013 - "Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells."
01/01/2013 - "In the present study, we show that the combination of doxorubicin with the cyclin-dependent kinase inhibitor P276-00 was synergistic at suboptimal doses in the non-small cell lung carcinoma (NSCLC) cell lines and induces extensive apoptosis than either drug alone in H-460 human NSCLC cells. "
11/01/2013 - "Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines."
|3.||Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/01/2012 - "Our studies thus provide evidence and rational that P276-00 alone or in combination is a potential therapeutic molecule to improve patients' outcome in mantle cell lymphoma."
07/01/2015 - "A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma."
01/01/2012 - "P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines."
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2012 - "Phase IIb clinical trials of P276-00 in combination with gemcitabine in pancreatic cancer patients are ongoing."
01/01/2012 - "The present study investigated the effect of the combination of P276-00 and gemcitabine in five pancreatic cancer cell lines. "
01/01/2012 - "The combination of gemcitabine followed by P276-00 was found to be highly to weakly synergistic in various pancreatic cancer cell lines as assessed by the combination index. "
01/01/2012 - "Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers."
|5.||Melanoma (Melanoma, Malignant)
03/01/2007 - "Studies to show tumor sensitivity using clonogenic assay in 22 human xenografts indicated that P276-00 was approximately 26-fold more potent than cisplatin, and further, it was also found to be active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers. "
|6.||Cell Cycle Proteins
|7.||Interleukin-6 (Interleukin 6)
|8.||Biological Markers (Surrogate Marker)
|9.||Valproic Acid (Valproate, Semisodium)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)